Considerations for Buffering Agent Selection for Frozen rAAV2 Mediated Gene Therapy Products.

Pandharipande, Pranav; Bhowmik, Tuhin; Singh, Nripen

Pandharipande, Pranav; Bhowmik, Tuhin; Singh, Nripen.

Afiliación

Pandharipande P; Voyager Therapeutics, Biopharmaceutical Development, Lexington, MA 02421, United States. Electronic address: ppandharipande@vygr.com.
Bhowmik T; Voyager Therapeutics, Biopharmaceutical Development, Lexington, MA 02421, United States.
Singh N; Voyager Therapeutics, Biopharmaceutical Development, Lexington, MA 02421, United States.

J Pharm Sci ; 110(10): 3535-3539, 2021 Oct.

Article en En | MEDLINE | ID: mdl-34126117

Asunto(s)

Dependovirus; Vectores Genéticos; Sistema Nervioso Central; Dependovirus/genética; Congelación; Terapia Genética

Palabras clave

Adeno-associated virus; Aggregation; Buffering agent; Capsid titer; Formulation; Isoelectric point; MADLS; Phosphate buffer; Pre-formulation; Tris Buffer; Turbidity; rAAV2

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dependovirus / Vectores Genéticos Tipo de estudio: Guideline / Prognostic_studies Idioma: En Revista: J Pharm Sci Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google